SCGB3A2 Human

The SCGB3A2 gene is located on chromosome 5 and encodes a protein that is a downstream target of thyroid transcription factor . The protein has a significant role in lung physiology and pathology. A single nucleotide polymorphism in the promoter region of the SCGB3A2 gene has been linked to increased susceptibility to asthma .

SCGB3A2 is known for its anti-inflammatory, anti-fibrotic, and growth factor activities . It binds to the scavenger receptor MARCO and can also bind to various pathogens, including Gram-positive and Gram-negative bacteria, as well as yeast . The protein strongly inhibits phospholipase A2 (PLA2G1B) activity, which contributes to its anti-inflammatory effects .

SCGB3A2 plays a crucial role in fetal lung development and maturation . It promotes branching morphogenesis during the early stages of lung development and has been shown to have anti-fibrotic activity in the lung . In transgenic mouse models, overexpression of SCGB3A2 has been demonstrated to accelerate the resolution of bleomycin-induced pulmonary fibrosis, suggesting its potential therapeutic use in treating pulmonary fibrosis .

Given its role in lung homeostasis and disease, SCGB3A2 has been studied for its potential therapeutic applications. Its anti-inflammatory and anti-fibrotic properties make it a promising candidate for treating conditions like asthma and pulmonary fibrosis . Additionally, SCGB3A2 has been shown to inhibit the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in the pituitary, indicating its broader physiological significance .

In summary, Secretoglobin Family 3A Member 2 (Human Recombinant) is a multifunctional protein with significant roles in lung development, inflammation, and fibrosis. Its potential therapeutic applications in respiratory diseases highlight its importance in medical research.